BioNanomatrix Pockets $23.3M in Series B Funding; to Open West Coast Office | GenomeWeb

By Julia Karow

This article, originally published March 17, has been updated with comments by the company's CSO at the Advances in Genome Biology and Technology conference last month.

BioNanomatrix has raised $23.3 million in a Series B round of equity financing, the company said last week.

Domain Associates led the round, joined by existing investors Battelle Ventures, Innovation Valley Partners, and KT Venture Group, as well as new investor Gund Investment.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.